摘要
目的 :研究卵巢癌细胞株SKOV 3ipl细胞在缺氧条件下的凋亡与适应性及其与细胞周期的关系。 方法 :贴壁培养卵巢癌细胞株SKOV 3ipl在缺氧条件下培养 ,于 0小时、8小时、16小时、2 4小时分别收集细胞 ,应用FITCAnnexinV/PI双染色 ,PIDNA染色流式细胞检测细胞凋亡及细胞周期的改变。结果 :缺氧培养 0小时、8小时、16小时、2 4小时凋亡细胞百分率分别为 (0 32± 0 0 1) % ,(8 2 9± 0 87) % ,(4 2 3± 0 75 ) % ,(0 5 9± 0 0 8% )。8小时及 16小时缺氧与 0小时相比 ,凋亡增加 (P值 <0 0 1) ;2 4小时后凋亡与 0小时无差异 (P >0 0 5 )。各时相细胞周期的变化表现为 :G1期阻滞 ,S期缩短 (8小时及 16小时缺氧与 0时相比 ,P <0 0 1) ,缺氧 2 4小时后 ,各细胞周期与 0小时相比无差异。结论 :卵巢癌细胞株SKOV 3ipl在缺氧培养 8到 16小时内发生凋亡与细胞周期G1期阻滞 ,2 4小时后对缺氧耐受、细胞周期阻滞解除 ;SKOV 3ipl细胞对缺氧的耐受及抗凋亡与细胞周期阻滞无关。
Purpose:To investigate hypoxia induced apoptosis and anti apoptosis in ovarian cancer cell line SKOV 3ipl cells and its correlation with cell cycle changes.Methods:The monolayer SKOV 3ipl cells plated in culture bottles were placed in an Anaerobic system insulated with 85% N 2,5% CO 2,10% H 2 and very low O 2 concentration (100 ppm). Apoptosis and cell cycles were measured with FITC Annexin V/PI double stain and DNA prep stain Flow cytometry in cells cultured in anaerobic condition. Results:Apoptosis in cells cultured in hypoxia condition for 0h,8h,16h,24h. were (0.32±0.01)%,(8.29±0.87)%,(4.23±0.75)%,(0.59±0.08)% respectively. Between 8h or 16h and 0h, P <0 01. For cell cycles in different time of hypoxia exposure for 0h,8h,16h,24h. G 1 phase were (52.92±1.79)%,(61.88±1.30)%,(78,35±1.42)%,(54.68±1.50)%,S phase were (42.36±2.40)%,(35.98±1.93)%,(11.92±2.05)%,(41.2±1.58)%;G 2 phase were (4.64±0.57)%,(2.12±1.13)%,(11.64±1.62)%,(4.14±0.84)% respectively. In G 1 phase and S phase, between 8h or 16h and 0h, P <0 01; in G1 phase,between 16h and 0h, P <0 01,8h and 0h. P <0.05.After 24hrs hypoxic exposure all cell cycles were the same as that for 0 hr.Conclusions:For ovarian cancer cell line SKOV 3ipl cells, apoptosis and cell cycle arrests were induced during hypoxic exposure for 8h~16h,after 24hrs, anti apoptosis and relief of cell cycle arrests developed. The ability of anti apoptosis and adaptation to hypoxia in SKOV 3ipl cells was not caused by cell cycle arrests.
出处
《中国癌症杂志》
CAS
CSCD
2002年第4期343-346,共4页
China Oncology